Peking University People's Hospital: Sarcoma, Ewing trials
The registry lists 11 Sarcoma, Ewing studies with Peking University People's Hospital as lead sponsor. 3 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 3No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing SarcomaRecruitingNCT07725783
- Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing SarcomaNot yet recruitingNCT07620431
- Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing SarcomaRecruitingNCT06340204Phase 1
- Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis AssessmentActive, not recruitingNCT06850506
- Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' ResistanceCompletedNCT06202599
- TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN LossStatus unknownNCT04690725Phase 1/2
- Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in BoneCompletedNCT03742063
- Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label UseCompletedNCT03491371Not applicable
- Anlotinib and Irinotecan for Ewing SarcomaStatus unknownNCT03416517Phase 1/2
- Irinotecan and Temozolomide for Ewing SarcomaStatus unknownNCT03359005Phase 2
- Clinical Evaluation for Sarcoma Originated From BoneStatus unknownNCT03358992